Effects of COX-2 inhibitors on ROS produced by Chlamydia pneumoniae-primed human promonocytic cells (THP-1)

Biochemical and Biophysical Research Communications

Volumn 325, Issue 4, 2004, Pages 1122-1130

  Mouithys Mickalad, Ange ^a   Deby Dupont, Ginette ^a,b   Dogne, Jean Michel ^a   De Leval, Xavier ^a   Kohnen, Stephan ^a   Navet, Rachel ^a   Sluse, Francis ^a   Hoebeke, Maryse ^a   Pirotte, Bernard ^a   Lamy, Maurice ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Chemiluminescence; Chlamydia pneumoniae; COX 2 inhibitors; Cyclooxygenase 2 enzyme; Electron paramagnetic resonance; Fluorescence; NADPH oxidase; Oxymetry; ROS

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; REACTIVE OXYGEN METABOLITE;

ARTICLE; CHEMOLUMINESCENCE; CHLAMYDOPHILA PNEUMONIAE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ELECTRON SPIN RESONANCE; FLUORESCENCE; HUMAN; HUMAN CELL; MONOCYTE; OXIMETRY; PRIORITY JOURNAL;

ARTERIOSCLEROSIS; CELL DIFFERENTIATION; CELL LINE; CHLAMYDOPHILA PNEUMONIAE; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FREE RADICALS; HUMANS; INFLAMMATION; MACROPHAGES; MONOCYTES; REACTIVE OXYGEN SPECIES; TETRADECANOYLPHORBOL ACETATE;

CHLAMYDIA; CHLAMYDOPHILA PNEUMONIAE;

EID: 8844270223     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.10.155     Document Type: Article

References (43)

1. A.J. Lusis Atherosclerosis Nature 407 2000 233 241
2. J.C. Fruchart, and P. Duriez Fundamental basis of atherosclerosis Ann. Endocrinol. (Paris) 62 2001 93 100
3. R. Ross Atherosclerosis-an inflammatory disease N. Engl. J. Med. 340 1999 115 126
4. D. Steinberg Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime Nat. Med. 8 2002 1211 1217
5. A.E. Becker, O.J. de Boer, and A.C. van der Wal The role of inflammation and infection in coronary artery disease Annu. Rev. Med. 52 2001 289 297
6. P. Saikku, M. Leinonen, K. Mattila, M.R. Ekman, M.S. Nieminen, P.H. Makela, J.K. Huttunen, and V. Valtonen Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction Lancet 2 1988 983 986
7. J. Danesh, R. Collins, and R. Peto Chronic infectious and coronary heart disease: is there a link? Lancet 350 1997 430 436
8. E. Speir, Z.-X. Yu, V.J. Ferrans, E.-S. Huang, and S.E. Epstein Aspirin attenuates cytomegalovirus infectivity and gene expression mediated by cyclooxygenase-2 in coronary smooth muscle cells Circ. Res. 83 1998 210 216
9. M. Kowalski Helicobacter pylori (H. pylori) infection in coronary artery disease: influence of H. pylori eradication on coronary lumen after percutaneous transluminal coronary angioplasty. The detection of H. pylori specific DNA in human coronary atherosclerotic plaque J. Physiol. Pharmacol. 52 2001 3 31
10. W.A. Boisvert The participation of inflammatory cells in atherosclerosis Drugs Today (Barc) 37 2001 173 179
11. M.V. Kalayoglu, and G.I. Byrne A Chlamydia pneumoniae component that induces macrophage foam cell formation is chlamydial lipopolysaccharide Infect. Immun. 66 1998 5067 5072
12. L.H. Arroyo, and R.T. Lee Mechanisms of plaque rupture: mechanical and biological interactions Cardiovasc. Res. 41 1999 369 375
13. D. Steinberg Low density lipoprotein oxidation and its pathobiological significance J. Biol. Chem. 272 1997 20963 20966
14. M.V. Kalayoglu, B. Hoerneman, D. LaVerda, S.G. Morrison, R.P. Morrison, and G.I. Byrne Cellular oxidation of low-density lipoprotein by Chlamydia pneumoniae J. Infect. Dis. 180 1999 780 790
15. T. Nguyen-Khoa, Z.A. Massy, V. Witko-Sarsat, S. Canteloup, M. Kebede, B. Lacour, T. Drüeke, and B. Descamps-Latscha Oxidized low-density lipoprotein induces macrophage respiratory burst via its protein moiety: a novel pathway in atherogenesis? Biochem. Biophys. Res. Commun. 263 1999 804 809
16. C.S. Baker, H.J. Hall, T.J. Evans, A. Pomerance, J. Maclouf, C. Creminon, M.H. Yacoub, and J.M. Polak Cyclooxygenase-2 is widely expressed in atherosclerotic lesions affecting native and transplantated human coronary arteries and colocalizes with inducible nitric oxide synthase and nitrotyrosine particularly in macrophages Arterioscler. Thromb. Vasc. Biol. 19 1999 646 655
17. M.E. Burleigh, V.R. Babaev, J.A. Oates, R.C. Harris, S. Gautam, D. Riendeau, L.J. Marnett, J.D. Morrow, S. Fazio, and Mc.-R.F. Linton Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice Circulation 105 2002 1816 1823
18. G.M. Chisolm, and D. Steinberg The oxidative modification hypothesis of atherosclerosis Free Radic. Biol. Med. 28 2000 1815 1826
19. D. Saha, K.R. Sekhar, C. Cao, J.D. Morrow, H. Choy, and M.L. Freeman The antiangiogenic agent SU5416 down-regulates phorbol ester-mediated induction of cyclooxygenase 2 expression by inhibiting nicotinamide dinucleotide phosphate oxidase activity Cancer Res. 63 2003 6920 6927
20. C. Deby, and G. Deby-Dupont Mechanisms of PGH synthase-1 (COX-1) activity and role of radical states P. Curtis-Prior The Eicosanoids 2004 Wiley New York 29 42
21. D. Zapolska-Downar, M. Naruszewicz, A. Zapolska-Downar, M. Markicwski, H. Bukowska, and B. Millo Ibuprofen inhibits adhesiveness of monocytes to endothelium and reduces cellular oxidative stress in smokers and non-smokers Eur. Clin. Invest. 30 2000 1002 1010
22. A. Mouithys-Mickalad, G. Deby-Dupont, M. Nys, M. Lamy, and C. Deby Oxidative processes in human promonocytic cells (THP-1) after differentiation into macrophages by incubation with Chlamydia pneumoniae extracts Biochem. Biophys. Res. Commun. 287 2001 781 788
23. H. Yamaguchi, S. Haranaga, R. Widen, H. Friedman, and Y. Yamamoto Chlamydia pneumoniae infection induces differentiation of monocytes into macrophages Infect. Immun. 70 2002 2392 2398
24. A. Mouithys-Mickalad, G. Deby-Dupont, M. Mathy-Hartert, Y. Habraken, M. Nys, Y. Henrotin, M. Lamy, and C. Deby Effects of glucocorticoids on the respiratory burst of Chlamydia primed THP-1 cells Biochem. Biophys. Res. Commun. 318 2004 941 948
25. M.J. Green, and A.O. Hill Chemistry of dioxygen Methods Enzymol. 105 1984 3 22
26. C.P. LeBel, H. Ischiropoulos, and S.C. Bondy Evaluation of the probe 2′,7′-dichlorofluorescin as an indicator of reactive oxygen species formation and oxidative stress Chem. Res. Toxicol. 5 1992 227 231
27. L.R. Silveira, L. Pereira-Da-Sylva, C. Juel, and Y. Hellstein Formation of hydrogen peroxide and nitric oxide in rat skeletal muscle cells during contractions Free Radic. Biol. Med. 35 2003 455 464
28. N. Parij, A.M. Nagy, P. Fondu, and J. Neve Effects of non-steroidal anti-inflammatory drugs on the luminol and lucigenin amplified chemiluminescence of human neutrophils Eur. J. Pharmacol. 352 1998 299 305
29. Y. Li, H. Zhu, and M.A. Trush Detection of mitochondria-derived reactive oxygen species production by the chemilumigenic probes lucigenin and luminol Biochim. Biophys. Acta 1428 1999 1 12
30. M. Asanuma, S. Nishibayashi-Asanuma, I. Miyazaki, M. Kohno, and N. Ogawa Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals J. Neurochem. 76 2001 1895 1904
31. C. Rota, C.F. Chignell, and R.P. Mason Evidence for free radical formation during the oxidation of 2′-7′-dichlorofluorescin to the fluorescent dye 2′-7′-dichlorofluorescein by horseradish peroxidase: possible implications for oxidative stress measurements Free Radic. Biol. Med. 27 1999 873 881
32. M.K. Cathcart Regulation of superoxide anion production by NADPH oxidase in monocytes/macrophages: contribution to atherosclerosis Artheriocler. Thromb. Vasc. Biol. 24 2004 23 28
33. E. Finkelstein, G.M. Rosen, E.J. Raukman, and J. Paxton Spin trapping of superoxide Mol. Pharmacol. 16 1979 676 685
34. A. Samuni, C.D.V. Black, C.M. Krishna, H.L. Maleich, E.F. Bernstein, and A. Russo Hydroxyl radical production by stimulated neutrophils reappraised J. Biol. Chem. 263 1988 13797 13801
35. M. Hoffman, and A.P. Autor Effect of cyclooxygenase inhibitors and protease inhibitors on phorbol-induced stimulation of oxygen consumption and superoxide production by rat pulmonary macrophages Biochem. Pharmacol. 31 1988 775 780
36. R. Maffei-Facino, M. Carini, G. Aldini, L. Saibene, and R. Morelli Differential inhibition of superoxide, hydroxyl and peroxyl radicals by nimesulide and its main metabolite 4-hydroxynimesulide Arzneimittelforschung 45 1995 1102 1109
37. A.M.L. Mouithys-Mickalad, S.X. Zheng, G.P. Deby-Dupont, C.M.-T. Deby, M.M. Lamy, J.-Y. Reginster, and Y.E. Henrotin In vitro study of the antioxidant properties of nonsteroidal anti-inflammatory drugs by chemiluminescence and electron spin resonance (ESR) Free Radic. Res. 33 2000 607 624
38. S.B. Abramson, P.J. Leszcynska, R.M. Clancy, M. Philips, and G. Weissmann Inhibition of neutrophil function by aspirin-like drugs (NSAIDs): requirement for assembly of heterotrimeric G proteins in bilayer phospholipid Biochem. Pharmacol. 47 1994 563 572
39. M. Bevilacqua, T. Vago, G. Baldi, E. Renesto, F. Dallegri, and G. Norbiato Nimesulide decreases superoxide production by inhibiting phosphodiesterase type IV Eur. J. Pharmacol. 268 1994 415 423
40. M.M. Krause, M.D. Brand, S. Krauss, C. Meisel, H. Vergin, G.-R. Burmester, and F. Buttgereit Nonsteroidal anti-inflammatory drugs and a selective cyclooxygenase 2 inhibitor uncouple mitochondria in intact cells Arthritis Rheum. 48 2003 1438 1444
41. T. Mahmud, S.S. Rafi, S.D.L. Cott, W.J.M. Rigglesword, and I. Bjarnason Nonsteroidal antiinflammatory drugs and uncoupling of mitochondrial oxidative phosphorylation Arthritis Rheum. 39 1996 1998 2003
42. R. Moreno-Sanchez, C. Bravo, C. Vasquez, G. Ayala, L.H. Silveira, and M.-M. Lavin Inhibition and uncoupling of oxidative phosphorylation by nonsteroidal anti-inflammatory drugs Biochem. Pharmacol. 57 1999 743 752
43. S. Papa, and V.P. Skulachev Reactive oxygen species, mitochondria, apoptosis and aging Mol. Cell. Biochem. 174 1997 319 350